Core Viewpoint - The article emphasizes that technological innovation will be the most significant trend in the pharmaceutical industry by 2026, with a focus on "technology first, medical devices take off" [1] Group 1: Innovative Drugs - The focus will be on revenue and performance realization, particularly on companies that exceed expectations in business development (BD) and cutting-edge technology platforms such as gene therapy, small nucleic acids, and universal/in vivo CAR-T [1] Group 2: Medical Devices - For medical devices, attention will be on inventory replenishment and bidding processes, particularly for surgical robots and endoscopes; consumables will benefit from centralized procurement, especially in innovative areas like neurointervention, peripheral intervention, and electrophysiology [1] Group 3: Changing Targets - With the central economic work conference highlighting the importance of domestic demand and building a strong domestic market, companies related to domestic pharmaceutical demand may experience a turning point [1] - Novartis' Pluvicto approval in China opens up possibilities for radioligand therapy (RDC), which, due to its different mechanism of action and high efficacy, may become a major direction in nuclear medicine development [1] Group 4: Biopharmaceutical ETF - The biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, and medical devices from the Shanghai and Shenzhen markets to reflect the overall performance of biopharmaceutical-related securities [1]

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 13.07 HKD, based on a 20x PE for 2025 [5]. Core Insights - The company is positioned for accelerated growth through a dual strategy of "independent research and global expansion," which enhances its international transformation potential [1][12]. - In 2024, the company achieved a revenue of 10.784 billion RMB, a year-on-year increase of 10.59%, and a net profit of 2.286 billion RMB, up 31.28% year-on-year, driven by increased demand for core products in nuclear medicine and cardiovascular precision intervention [21]. Summary by Sections 1. Company Overview - Founded in 1939, the company operates across three main sectors: nuclear medicine for tumor diagnosis and treatment, cardiovascular precision intervention, and pharmaceutical technology [1][12]. - The company has over 10,000 employees globally and more than 30 subsidiaries, with a diverse product portfolio exceeding 200 items in the medical insurance directory [1][12]. 2. Pharmaceutical Technology - The company is focused on developing innovative drugs in respiratory and critical care, with STC3141 showing promise as a new treatment for sepsis [2][31]. - The global market for sepsis treatment is projected to grow from 12.54 billion USD in 2024 to 19.37 billion USD by 2032, indicating significant unmet clinical needs [40]. 3. Nuclear Medicine - The company has established a complete industrial chain in nuclear medicine, with its core product, Yttrium-90 microsphere injection, rapidly gaining market traction since its approval in 2022 [3][4]. - The company is advancing multiple nuclear medicine products through clinical trials, including TLX591 for prostate cancer and GPN02006 for liver cancer diagnosis, positioning itself in the global first-tier of development [4][12]. 4. Financial Forecast - Revenue projections for 2025-2027 are 12.405 billion RMB, 13.729 billion RMB, and 15.113 billion RMB, respectively, with net profits expected to be 2.121 billion RMB, 2.396 billion RMB, and 2.773 billion RMB [5].